newswire, breaking biotechnology and pharma news

Monday, September 27, 2010 - Biotech Stocks on the Move: High Volume Traders; (OTCBB: UVFT), (OTCBB: KBLB), (NASDAQ:SGEN), (NASDAQ:GENZ) - Biotech Stocks on the Move: High Volume Traders; (OTCBB: UVFT), (OTCBB: KBLB), (NASDAQ:SGEN), (NASDAQ:GENZ)

Category: Investment, Biotech
Subscribe to Investor Ideas Newswire
Visit this company:
Point Roberts, WA - September 27, 2010 ( Newswire, -, a leader in sector research for investors, reports on recent Volume Leading Biotech/ Pharma Stocks news and trading for September 27th on the OTCBB and NASDAQ Markets. Top gainers included Seattle Genetics, Inc. (NASDAQ: SGEN), one of the most advanced stocks on the in morning trading.

Biotech Stocks include UV Flu Technologies, Inc., (OTCBB: UVFT), Seattle Genetics Inc (NASDAQ:SGEN), Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB), and Genzyme Corp. (NASDAQ:GENZ)

Sector Snapshot: (Trading at time or release)
UV Flu Technologies, Inc., (OTCBB: UVFT) trading at $ 0.34, up 0.02 (6.25%)
Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB), trading at $ 0. 2410, up 0.0229 (10.04%) on Volume of 13,387,394 shares
Seattle Genetics Inc. (NASDAQ: SGEN), trading at $14.91, up 2.75 (22.62%) on Volume of 7,333,439 shares
Genzyme Corp. (NASDAQ:GENZ) trading at $ 71.75, up 0.15 (0.21%)

Biotech Stocks to Watch; Recent News
UV Flu Technologies, Inc., (OTCBB: UVFT) Key Highlights and Recent Press
UV Flu Technologies, Inc., (OTCBB: UVFT) is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. UV Flu is committed to providing clean air to improve health and prevent the spread of disease.
The company recently announced that in response to recent outbreaks of drug resistant superbugs such as NDM-1, and persistent occurrences of highly contagious strains of bacteria such as MRSA, the Company is implementing a national campaign to inform the public how its ViraTech UV-400 indoor air purifier significantly helps reduce exposure risks.
UV Flu Technologies, Inc., Key Highlights
FDA Approved as a Class II Medical device
Extensive testing by EPA and FDA certified laboratories confirm the proprietary system has over 99% effectiveness of eliminating bacteria
The Company's strategic differentiators include excellent independent test results proving the effectiveness and safety of its products, proprietary design, and FDA market clearance approving the sale of its products as medical devices.
The Company has been issued U.S. Patent No. 6939397 with 43 claims covering its innovative removable cartridge, housing, UV chamber, UV radiation source and baffle technology.
UV Flu's products are environmentally friendly. The energy efficient system does not use or produce ozone, uses less energy than a 100 watt light bulb and can qualify for Green Building programs.
Experts have warned that a new type of drug-resistant superbug is emerging. NDM-1 is a gene carried by bacteria that makes the strain resistant to some of the most powerful antibiotics. NDM-1 can easily now jump from one strain of bacteria to another.
Latest News:
"UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that the company and its flagship UV-400 air purification system will be featured on a segment of the “Designing Spaces” TV Show, to be aired nationally during the 4th quarter. The show, to be aired on the Women’s Entertainment channel, is scheduled for the holiday season and is expected to reach up to 75 million households."

Full Article:
Seattle Genetics Inc (NASDAQ:SGEN)
Seattle Genetics Inc (NASDAQ:SGEN) Recent News: “Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502 - News), today announced positive top-line results from the pivotal trial of single-agent brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC) targeted to CD30. The trial was conducted in 102 relapsed or refractory Hodgkin lymphoma (HL) patients.
Seventy-five percent of patients in the pivotal trial achieved an objective response as assessed by an independent central review, the primary endpoint of the trial. The median duration of response was greater than six months. The safety profile of brentuximab vedotin in this trial was generally consistent with prior clinical trial experience. A more complete data set will be presented at an upcoming scientific meeting."
Full News
About Seattle Genetics Inc (NASDAQ:SGEN):
Seattle Genetics is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company’s lead product candidate, brentuximab vedotin, is being evaluated in a variety of lymphoma treatment settings including the relapsed and refractory Hodgkin lymphoma indication for which top-line pivotal data have been reported. In addition, Seattle Genetics has four other clinical-stage programs: SGN-75, ASG-5ME, dacetuzumab (SGN-40) and SGN-70. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, MedImmune, a subsidiary of AstraZeneca, Millennium: The Takeda Oncology Company and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at
Market Snapshot: (at time of release)
Dow 10,832.48 -27.78 -0.26% Nasdaq 2,372.96 -8.26 -0.35% S&P 500 1,144.53 -4.14 -0.36% 10 Yr Bond (%) 2.5300% -0.8200 Oil 75.68 -0.81 -1.06% Gold 1,297.00 +1.00 +0.08%
About is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. is known for its comprehensive stock directories in each sector and sector specific newswires.
Research more biotech stocks at the Biotech stocks Directory:
About our Biotech investor portal: Portal is a global meeting place for investors and industry following the sector, within Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (eight hundred) is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclaimer: Disclosure:
C Van Zant: 800-665-0411 -
Source -

No comments:

Post a Comment